Morgan Paull

Morgan Paull currently serves as Chief Operating Officer at GondolaBio since August 2024 and has held various leadership roles at Portal Therapeutics since June 2020, including Chief Operating Officer, SVP of Business Development and Operations, and VP of Business Development and Operations. Additionally, Morgan is the SVP of Strategy and Operations at QED Therapeutics and BridgeBio and has served as VP of Strategy and Operations at both organizations since November 2021 and March 2020, respectively. Prior experience includes a consultant role at McKinsey & Company and cofounding Mendo, Inc., a microfluidic liquid-handling company, with a foundation in technology from Stanford. Educational qualifications include a Master of Science in Bioengineering and a Master of Science in Management Science and Engineering from Stanford University, along with a Bachelor of Science in Engineering Science from Harvard University. Early experiences include research and internship roles at prestigious institutions such as the Harvard School of Public Health, Wyss Institute, Joint BioEnergy Institute, and the United States Senate.